Article Text

other Versions

PDF
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
  1. Robert L Avery
  1. Correspondence to Dr Robert L Avery, California Retina Consultants, 515 E. Micheltorena St., Ste. C, Santa Barbara, CA 93103, USA; Avery1{at}jhu.edu

Abstract

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.

  • Retina
  • Pharmacology
  • Drugs
  • Macula
  • Angiogenesis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.